Published in Cancer Immunol Immunother on October 28, 2011
Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther (2013) 0.90
Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res (2015) 0.79
Population-based estimates of survival and cost for metastatic melanoma. Curr Oncol (2015) 0.77
The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma. Cancer Manag Res (2012) 0.76
Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152. Cell Death Dis (2016) 0.76
Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins. F1000Res (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med (1998) 4.65
Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med (1994) 4.20
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A (2000) 3.00
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 2.99
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol (2003) 2.67
Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res (2004) 2.19
Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer (2001) 2.10
The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res (2007) 1.63
Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther (2004) 1.56
The universal character of the tumor-associated antigen survivin. Clin Cancer Res (2007) 1.50
Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother (2005) 1.47
Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer (2009) 1.40
Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res (2005) 1.35
Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother (2004) 1.35
Immune selection after antigen-specific immunotherapy of melanoma. Surgery (1999) 1.34
Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett (2001) 1.29
Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res (2008) 1.28
Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Res (2003) 1.25
Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol (2005) 1.23
Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov (2005) 1.22
SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J Biol Chem (2002) 1.17
Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals. Melanoma Res (1996) 1.16
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A (2003) 1.14
Livin/ML-IAP as a new target for cancer treatment. Cancer Lett (2007) 1.06
The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res (2003) 1.06
KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem Biophys Res Commun (2000) 1.03
Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene. Oncogene (2003) 1.01
Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Clin Cancer Res (2005) 0.95
HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer (2004) 0.94
The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses. J Invest Dermatol (2004) 0.94
The anti-apoptotic livin gene is an important determinant for the apoptotic resistance of non-small cell lung cancer cells. Lung Cancer (2006) 0.94
Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin Chim Acta (2005) 0.92
Survivin--a universal tumor antigen. Histol Histopathol (2002) 0.89
Expression of inhibitor of apoptosis protein Livin in renal cell carcinoma and non-tumorous adult kidney. Br J Cancer (2007) 0.88
Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur J Immunol (2003) 0.86
Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. Lung Cancer (2005) 0.86
The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines. Cancer Immunol Immunother (2008) 0.83
Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas. J Clin Pathol (2005) 0.81
Detection of anti-livin antibody in gastrointestinal cancer patients. Clin Chem (2003) 0.81
Melanoma vaccines: prospects for the treatment of melanoma. Expert Opin Investig Drugs (1997) 0.78
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Identification of cells initiating human melanomas. Nature (2008) 8.28
Open mesh versus laparoscopic mesh repair of inguinal hernia. N Engl J Med (2004) 8.24
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Electric-field control of local ferromagnetism using a magnetoelectric multiferroic. Nat Mater (2008) 7.23
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Watchful waiting vs repair of inguinal hernia in minimally symptomatic men: a randomized clinical trial. JAMA (2006) 6.34
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med (2009) 4.16
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol (2011) 3.53
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res (2013) 3.02
Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity (2012) 2.99
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res (2012) 2.68
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res (2012) 2.63
KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res (2008) 2.57
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol (2011) 2.51
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol (2003) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2012) 2.04
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Does resident post graduate year influence the outcomes of inguinal hernia repair? Ann Surg (2005) 2.01
Sentinel lymph nodes in a swine model with melanoma: contrast-enhanced lymphatic US. Radiology (2004) 1.95
Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen. J Allergy Clin Immunol (2009) 1.91
Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist (2013) 1.91
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A (2006) 1.88
Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res (2005) 1.87
A novel method for the isolation of skin resident T cells from normal and diseased human skin. J Invest Dermatol (2006) 1.86
Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res (2010) 1.83
Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol (2013) 1.83
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 1.80
Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res (2008) 1.73
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol (2008) 1.70
Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med (2008) 1.67
Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics (2007) 1.67
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood (2013) 1.67
Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease. Blood (2009) 1.67
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med (2015) 1.64
Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res (2008) 1.63
Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant (2003) 1.62
Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. Neurology (2013) 1.62
VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res (2011) 1.62
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res (2013) 1.53
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51
Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood (2005) 1.51
Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood (2002) 1.47
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.44
Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res (2007) 1.44
CCR2 is required for CD8-induced graft-versus-host disease. Blood (2005) 1.43
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
Regulation of myogenic progenitor proliferation in human fetal skeletal muscle by BMP4 and its antagonist Gremlin. J Cell Biol (2006) 1.42
Proficiency of surgeons in inguinal hernia repair: effect of experience and age. Ann Surg (2005) 1.37
Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med (2011) 1.37
Melanoma. J Natl Compr Canc Netw (2009) 1.37
T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med (2002) 1.35
Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev (2008) 1.34
Human insulin analog--induced lipoatrophy. Diabetes Care (2007) 1.34
Visual analog scales for assessing surgical pain. J Am Coll Surg (2005) 1.32
Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood (2002) 1.31
NOD2 regulates hematopoietic cell function during graft-versus-host disease. J Exp Med (2009) 1.30
When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst (2012) 1.28
Fourteen-year follow-up of a patient-fitted total temporomandibular joint reconstruction system. J Oral Maxillofac Surg (2007) 1.27
The development of a clinical trial to determine if watchful waiting is an acceptable alternative to routine herniorrhaphy for patients with minimal or no hernia symptoms. J Am Coll Surg (2003) 1.25
Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response. Proc Natl Acad Sci U S A (2009) 1.23
Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res (2013) 1.23
ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res (2011) 1.23
Expression of the embryonic stem cell transcription factor SOX2 in human skin: relevance to melanocyte and merkel cell biology. Am J Pathol (2009) 1.22